Clinical Trials · NCT01075282
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 810
- Start date
- Feb 2010
- Locations
- 78 sites, 20 countries
- Primary endpoint
- Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)